#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Internal Medicine - Issue 11/2014

Reviews

926

New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes

Zdeněk Rušavý

931

Prevention of cardiovascular diseases in clinical practice: is it possible to achieve improvement?

Tomáš Štulc, Michaela Šnejdrlová, Richard Češka

937

Residual cardiovascular risk markers

Hana Rosolová, Barbora Nussbaumerová

942

New aspects of hormone replacement therapy

Tomáš Fait

949

News in lipid lowering treatment

Michal Vrablík, Richard Češka

958

Non-pharmacological treatment – results from Poděbrady

Lukáš Zlatohlávek, Michal Vrablík, Zuzana Urbanová, Hana Pejšová, Jaroslav Hubáček, Richard, Češka

963

Familial hypercholesterolemia – past and present.
My experiences and findings in our group of patients with familial hypercholesterolemia

Richard Češka, Michal Vrablík, Tereza Altschmiedová, Martina Prusíková, Zuzana Urbanová, Josef Šobra

970

LDL-apheresis in the treatment familial hypercholesterolemia

Vladimír Bláha, Milan Bláha, Miriam Lánská, Eduard Havel, Pavel Vyroubal, Zdeněk Zadák, Pavel Žák, Luboš Sobotka

977

Extended options of anticoagulant treatment in thromboembolism

Debora Karetová, Jan Bultas

985

What do have arterial and venous disease in common?

Jan Piťha, Ondřej Auzký, Karel Roztočil

991

Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey

Michal Vrablík, Zdeněk Chmelík, Věra Lánská

Actualities

999

Adherence of type 2 diabetes patients on insulin analogues application: missed dose, time imprecision and dose reduction
The results of GAPP2^TM(Global Attitudes of Physicians and Patient) survey in the Czech Republic

Martin Prázný

Internal Medicine

Issue 11

2014 Issue 11

Most read in this issue

#ADS_BOTTOM_SCRIPTS#